Are you Dr. Frontiera?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1211 Fish Hatchery Rd
Madison, WI 53715Phone+1 608-252-8000Fax+1 608-410-2905
Summary
- Dr. Michael Frontiera, MD is an oncologist in Madison, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Colorado, and California. He is affiliated with SSM Health St. Mary's Hospital and Prairie Ridge Health, Inc..
Education & Training
- University of ColoradoFellowship, Hematology and Medical Oncology, 1983 - 1986
- University of California (San Francisco)/FresnoResidency, Internal Medicine, 1980 - 1983
- University of Kansas School of MedicineClass of 1980
Certifications & Licensure
- CA State Medical License 1981 - Present
- WI State Medical License 1986 - 2025
- CO State Medical License 1983 - 1987
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Publications & Presentations
PubMed
- 252 citationsPhase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089Daniel G. Haller, Paul J. Catalano, Mark Allen O'Rourke, Michael S. Frontiera, Don V. Jackson
Journal of Clinical Oncology. 2005-12-01 - 24 citationsA randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert C. Whorf, Mark Keaton
Clinical Breast Cancer. 2011-08-01 - 20 citationsRandomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.Joan H. Schiller, Barry E. Storer, Robert Dreicer, Debra Rosenquist, Michael Frontiera
Journal of the National Cancer Institute. 1989-11-15
Professional Memberships
- Member
Other Languages
- Spanish, Spanish